Mineralys Therapeutics (NASDAQ: MLYS) net income
Mineralys Therapeutics reported a net loss of $154.7m for fiscal 2025; in fiscal 2024 it reported a net loss of $177.8m. Earnings per share were −$2.29.
Mineralys Therapeutics's best year of the last 4 was fiscal 2022. It reported a loss in 4 of those 4 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$154.7m | — | — | −$2.29 |
| 2024 | −$177.8m | — | — | −$3.66 |
| 2023 | −$71.9m | — | — | −$1.99 |
| 2022 | −$29.8m | — | — | −$5.77 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Mineralys Therapeutics net income compared with its sector
By net income for its latest fiscal year, Mineralys Therapeutics ranks 384th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 382nd | UroGen Pharma | −$153.5m | −139.8% |
| 383rd | Crescent Biopharma | −$153.9m | −1,419.6% |
| 384th | Mineralys Therapeutics | −$154.7m | — |
| 385th | Spyre Therapeutics | −$155.2m | — |
| 386th | Atea Pharmaceuticals | −$158.3m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Mineralys Therapeutics
- How much did Mineralys Therapeutics earn in fiscal 2025?
- Mineralys Therapeutics reported a net loss of $154.7m for fiscal 2025. In fiscal 2024 it reported a net loss of $177.8m.
- What are the earnings per share of Mineralys Therapeutics?
- They were −$2.29 in fiscal 2025, compared with −$3.66 in fiscal 2024.
- Where does Mineralys Therapeutics rank in its sector by net income?
- It ranks 384th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Mineralys Therapeutics come from?
- From the annual report (Form 10-K) that Mineralys Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Mineralys Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Mineralys Therapeutics: the Mineralys Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.